Publications by authors named "W Fiskus"
Rising blast-percentage or secondary (s) AML transformation (sAML) in MPNs leads to JAK inhibitor (JAKi) therapy-resistance and poor survival. Here, we demonstrate that the CDK7 inhibitor (CDK7i) SY-5609 treatment depletes phenotypically-characterized post-MPN-sAML stem/progenitor cells. In the cultured post-MPN sAML SET2 and HEL as well as patient-derived (PD) post-MPN-sAML cells, SY-5609 treatment inhibited growth and induced lethality, while sparing normal cells.
View Article and Find Full Text PDFArticle Synopsis
- Aberrant expression of HOX and MEIS1 family genes in certain leukemias disrupts normal blood cell differentiation and contributes to leukemia development.
- Menin inhibitors can target the interaction between KMT2A and menin, reducing the abnormal expression of key factors and promoting differentiation in these leukemias.
- A collaborative effort among pediatric and adult specialists aims to advance menin inhibitors in treatment, offering a comprehensive overview of clinical trials and advocating for inclusive trial designs for youth.
Article Synopsis
- BRG1 and BRM are key ATPases in chromatin remodeling that help regulate gene expression in acute myeloid leukemia (AML) stem/progenitor cells.
- FHD-286 is a new oral drug that targets BRG1/BRM and shows potential in treating AML, particularly in cases with specific mutations (MLL1r or mtNPM1) by inducing cancer cell differentiation and death.
- Combining FHD-286 with other treatments, like decitabine or BET inhibitors, further enhances survival and reduces cancer burden in AML models without significant side effects, making it a promising therapeutic approach.
Article Synopsis
- * Researchers created the first AML cell line from FPD-MM patients (GMR-AML1) and found increased activity of important genes like MYB and MYC, as well as markers indicative of leukemia stem cells.
- * Treatments with homoharringtonine (HHT), mebendazole (MB), and volasertib showed promising results in reducing leukemia cell survival and improving outcomes in a mouse model, suggesting potential therapeutic strategies for FPD-MM.